Independent SMO Panthera Biopartners continues to expand its network of clinical trial sites

·         Panthera’s second clinical trial site in the UK, in North Manchester is open for business.

·         As a standalone site ideal for existing or new trials with much lower contamination risk during COVID-19

Panthera is on track to have a network of sites open across the UK by the end of the year and is continuing to invest in growth despite the increasingly challenging environment created by the COVID-19 pandemic.

CEO Stuart Young commented “We are adapting our plans to support the efforts of those tackling the COVID-19 pandemic while also pursuing the long-term goal to provide exemplar, independently run clinical trial sites across the UK and beyond. We are already able to provide top class clinical facilities in Preston and Manchester and are looking to build that network much further putting the patient at the heart of what we do.”

He continues, “This pandemic has highlighted the need for more clinical research across the globe. We are keen to play our part to help in the short term in any way we can. However, in the longer term, we are focussed on providing our customers in pharma and CROs with a better solution.”

Panthera, as an independent SMO, with one of the most experienced teams in the industry, has attracted the attention of all the major CROs and pharma companies, and is offering sites for their traditional specialities in vaccines, general medicine and primary care conditions.

Panthera is also in advanced discussions in providing specialist secondary care sites for trials in neurology and oncology.

Founded by Dr Ian Smith, founder of Synexus, and Prof. John Lyon previously a senior global executive in Covance, the team also includes CCO Jane Restorick who was previously the global COO at Synexus and CEO Stuart Young, former MD Synexus UK.

Stephen Doherty leads the team of experienced GCP trained staff at the new North Manchester site, which will focus on trials in conditions treated in primary care including cardiac disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine.

The site facilities will include seven consulting rooms, a fully equipped laboratory, with state of the art research facilities and ample parking for patients.